『AI Validating AI: The Future of Compliance in Life Sciences』のカバーアート

AI Validating AI: The Future of Compliance in Life Sciences

AI Validating AI: The Future of Compliance in Life Sciences

無料で聴く

ポッドキャストの詳細を見る
Artificial intelligence is moving fast—but in regulated life science environments, speed without trust is a non‑starter. In this episode of The Life Science Effect, host Steven Vinson reacts to a recent EY article on AI validation in pharmaceutical and biotech settings and explores a fascinating question: Can AI actually be used to validate other AI systems? Steven walks through how regulators are beginning to rethink traditional validation models to accommodate AI's non‑deterministic nature, where the same input can produce different, but still acceptable, outputs. Drawing parallels to earlier industry shifts like electronic records, he explains why clear regulatory frameworks are essential for innovation without compromising patient safety. The conversation dives into EU‑specific regulations such as GMP Annex 11, Annex 22, and the EU AI Act, while contrasting Europe's proactive approach with the more hands‑off posture emerging in the U.S. Along the way, Steven offers practical insight for entrepreneurs, engineers, and investors navigating AI in regulated environments, and why "robots testing robots" might be less science fiction than it sounds. EY ARTICLE: GxP and AI tools: Compliance, Validation and Trust in Pharma | EY - Switzerland MUSIC used under the Creative Commons Attribution 4.0 International License: Acid Jazz-Kevin MacLeod Acoustic Motivation by Corna Media Key Discussion Points Why AI validation is different from traditional computer system validation What "acceptable ranges of output" mean for regulated AI systems Using AI to validate AI: hype vs. reality Overview of EU regulations: GMP Annex 11, Annex 22, and the EU AI Act Lessons from the transition from paper records to electronic systems Why regulatory clarity enables innovation in pharma and biotech Notable Quotes "AI is a tool—and tools still have to be validated." "With AI, different outputs are okay, as long as they fall within what's acceptable." "I just love the idea of robots testing robots." "ChatGPT does not equal AI." "AI is a fantastic tool, but it's not the solution to every problem." Call to Action If you're working with AI in regulated environments—or thinking about it—subscribe to The Life Science Effect, leave a review, and share this episode with your team. Want to join the conversation? Email steven.vinson@bpm-associates.com or visit thelifescienceeffect.com. Transcript [00:00:01] You are about to experience The Life Science Effect, Season 2, brought to you by our presenting sponsor, BPM Associates. [00:00:16] Extraordinary people. Relationships that matter. Important change for a better world. The joy of belonging. Life, science, leadership. [00:00:29] A few years ago, when we all started learning about ChatGPT and were amazed by it, my first thought was: how can this be used for GMP validation in the pharmaceutical and medical device industries? For testing the equipment that makes products, and the systems used to manage manufacturing and R&D. [00:00:57] I asked a colleague who works in the quality and regulatory space for pharma and medical devices, "What are you hearing? What are you seeing?" He said, "AI is a tool, and you have to validate the tools you use for testing." [00:01:15] That led to a bigger question. He had asked someone from the FDA at a conference: how do you validate an AI when most of us—even the people who design AI—aren't 100% sure what's going on inside it? [00:01:31] Fast forward a few years. I've been reading articles and digging into this topic, and I came across a really interesting piece—more like a blog post—on EY's website. I'll link to it in the show notes. [00:01:47] It's written by Martin Blank, a partner at EY in Switzerland, focused on life science regulatory work. EY is one of the large global consulting firms, similar to Accenture. Because of his background, the article has more of an EU perspective, but much of it applies to the U.S. as well—though the U.S. may be a bit behind. [00:02:09] The article is titled "AI Validation in Pharma: Maintaining Compliance and Trust." It caught my attention for a few reasons. I was actively looking for examples of how AI is being used, and I wanted something relatively recent. This was published in October 2025, and I'm recording this in early 2026, so it felt timely. [00:02:32] What really grabbed me was that he talks about using AI to validate AI. [00:02:46] It's kind of like robot-on-robot violence. [00:02:50] I, for one, welcome our robot overlords. [00:02:58] I read the article and thought I'd share my reactions with you. The big takeaway right away is that AI can absolutely be validated. That answers the question from a few years ago. The real question is: how? [00:03:25] In traditional computer system validation, you provide a specific input and expect a specific output that matches exactly. With AI, you might give the same input multiple times and get different ...
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません